Published Aug 19, 2019

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Member News
Copy The Link to the  Article
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Copy The Link to the  Article

Related or similar articles

View more News
April 29, 2024

Lab Space Boston: Navigating Opportunities and Challenges

Hello, fellow science enthusiasts! If you're on the hunt for the perfect laboratory space in greater Boston and Cambridge, you've come to the right place. As experts in the field, we at Labshares know a thing or two about navigating the opportunities
Labshares News
April 25, 2024

Laboratory Space for Emerging Biotechs:  Best Practices and Tips from Labshares 

Labshares News
November 2, 2018

Life Sciences Co-Working Incubator Labshares Launches in Newton

A new office and laboratory incubator for emerging biotechnology and life science companies has just opened in Newton’s Charles River Mill District.
Labshares News